LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
Authors:
- Y. VanoYVY. Vano
- R.T. ElaidiRER.T. Elaidi
- M. BennamounMBM. Bennamoun
- C.M. ChevreauCCC.M. Chevreau
- D. BorchielliniDBD. Borchiellini
- D. PannierDPD. Pannier
- D. MailletDMD. Maillet
- M. Gross-GoupilMGM. Gross-Goupil
- C. TournigandCTC. Tournigand
- B. LaguerreBLB. Laguerre
- P. BarthélémyPBP. Barthélémy
- F. JolyFJF. Joly
- 1 September 2020
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 31, S1157